Collectively, these data indicate that the CDK19 expression level can serve as a valuable prognostic biomarker in HCC patients and that the prognostic significance varies depending on different clinical subgroups, which can guide our clinical practice in a personized manner. The gene discussed is CDK19; the disease is hepatocellular carcinoma.